Anti-ACEH antibody produced in rabbit
Anti-ACEH antibody produced in rabbit Basic information
- Product Name:
- Anti-ACEH antibody produced in rabbit
- Synonyms:
-
- Anti-ACE2 antibody produced in rabbit
- Anti-ACEH antibody produced in rabbit
- Anti-ACE-related carboxypeptidase antibody produced in rabbit
- Anti-Angiotensin-converting enzyme 2 precursor antibody produced in rabbit
- Anti-Angiotensin-converting enzyme homolog antibody produced in rabbit
- Anti-ACEH
- Anti-Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2
- Anti-DKFZP434A014
- MW:
- 0
- Mol File:
- Mol File
Anti-ACEH antibody produced in rabbit Chemical Properties
- storage temp.
- -20°C
- form
- buffered aqueous solution
Anti-ACEH antibody produced in rabbit Usage And Synthesis
Uses
All Prestige Antibodies?Powered by Atlas Antibodies is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .
General Description
Angiotensin-converting enzyme-2 (ACE2) is a homolog of angiotensin-I converting enzyme (ACE). ACE2 is a member of the renin-angiotensin system (RAS) which performs functions similar to carboxypeptidase. This 805 amino acid protein is localized in human kidney. The ACE2 gene is located at human chromosome Xp22.2. It contains a N-terminal peptidase domain (PD) and the C-terminal collectrin-like domain (CLD).
Biochem/physiol Actions
Angiotensin-converting enzyme (ACE2) catalyzes the degradation of angiotensin (Ang) II to Ang (1-7). The deficiency ACE2 or its inhibition by ang II is implicated in the pathogenesis of cardiac hypertrophy and myocardial dysfunction. ACE2 is multifunctional and is incapable of hydrolyzing bradykinin. In patients with CTD (connective tissue disease), serum autoantibodies suppress ACE2, which leads to a decrease in the physiological levels of vasoprotective agent Ang (1-7) in the vascular milieu. Activation or administration of ACE2 in patients with CTD may serve as a therapeutic method for treating pulmonary arterial hypertension (PAH), or persistent digital ischemia. It also plays a regulatory role in lung diseases and pulmonary fibrosis. The human ACE2 receptor is recognized by severe acute respiratory syndrome (SARS-CoV) coronaviruses (CoVs) 2. This interaction paves a way for the transmission of infection.
Anti-ACEH antibody produced in rabbitSupplier
- Tel
- 021-61415566 800-8193336
- orderCN@merckgroup.com
- Tel
- 18818239863 18818239863
- 3171921642@qq.com
- Tel
- 021-69985186 13611928337
- 3427709316@qq.com